Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 5/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824432 | 0.92 | CCR1 (0.48) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL15478312 | 0.91 | CCR1 (0.48) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL14419972 | 0.90 | CCR1 (0.47) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL15478348 | 0.90 | CCR1 (0.50) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL12121845 | 0.89 | CCR1 (0.51) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL10287557 | 0.88 | CCR1 (0.49) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL13824434 | 0.88 | CCR1 (0.48) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL14579627 | 0.88 | CCR1 (0.49) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL14420122 | 0.88 | CCR1 (0.49) | CCR1CHRM2CCR5S1PR5HRH1 | |
| SCHEMBL13824440 | 0.88 | CCR1 (0.52) | CCR1CHRM2CCR5S1PR5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CCR1 9/4885CHRM2 747/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.